New Issue: Orbital Catastrophe Ahead? Read Now

DNA Spheres Light Up to Detect Cancer

Ball-shaped molecules release flares when they encounter malignancy

Join Our Community of Science Lovers!

Cancer travels. Large tumors shed cells that move through the body and seed new malignancies. Now scientists are tinkering on the nanoscale to build unusual spheres made of DNA—a molecule that became famous as another shape, the double helix—that can find, tag and potentially kill off these tumor cells.

The spheres look a bit like toothpicks stuck in a small Styrofoam ball. The toothpicks are really a dense crowd of single DNA strands jutting out from a central core. The strands are chosen for their ability to bind to complementary DNA in cancer cells. When a bond happens, it displaces tiny light-emitting molecules stuck to the tips of the DNA in the sphere, essentially sending up a flare that indicates the presence of cancer. The brighter the flare, the more cancer DNA that is present, says Chad A. Mirkin, a chemist and director of the International Institute for Nanotechnology at Northwestern University, who has spearheaded the research.

These encounters occur in a sample of a patient's blood. When the spheres run into a cell, they move through pores in the cell membrane into the interior. There, the DNA that forms that outer rim has a much higher chance of encountering and latching on to cancer DNA than isolated strands would.* Spherical nucleic acids “bind to other nucleic acids 100 times more strongly,” Mirkin says.


On supporting science journalism

If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.


Mirkin's spheres, also called Nanoflares, are already being used by hospitals for rapid cancer diagnosis. Other systems fish out dead tumor cells based on proteins on their outer surfaces, but because these spheres identify live cells, Mirkin says, scientists could test how the cells respond to different drugs and eventually develop personalized treatments based on the results.

*Editor's Note (6/2/15): This sentence was edited after it was posted online to remove an error that appeared in the original print version.

Subscribe to Support Independent Journalism

Great science journalism requires human expertise, time, effort and creativity. And it costs money. That’s why I and the journalists here at Scientific American hope you’ll join our community.

When you subscribe, you are supporting staff and freelance journalists who are passionate about telling science stories that are true, important and compelling. Our editors and reporters are often experts in their fields, which means they understand the nuances of big discoveries and can untangle the breakthroughs from the hype. With a subscription, you are also supporting rigorous fact-checking to ensure the words we publish are precise and accurate. And you’re supporting original illustrations, graphics and photos that bring you closer to an advanced laboratory, an ice sheet in Antarctica or a space mission in orbit. You’re helping us craft other types of high-quality journalism as well: Our newsletters are carefully written, edited and curated by staffers you have or will come to know and love. Our Science Quickly podcast is based on original reporting, collaboration with editors and scientists and exacting production.

Subscriptions keep this engine running so we can continue to deliver thoughtful, rigorous and independent science journalism to you. In an era of viral misinformation, this work is crucial. If you value what we do, I hope you’ll consider joining us as a subscriber

Thank you,

Jeanna Bryner, Editor in Chief, Scientific American

Subscribe